Trial Profile
A Phase II Randomized, Placebo-Controlled, Multicenter Trial to Evaluate the Protective Function of a CMV-MVA Triplex Vaccine in Recipients of an Allogeneic Hematopoietic Stem Cell Transplant
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 18 Mar 2024
Price :
$35
*
At a glance
- Drugs MVA CMV (Primary)
- Indications Cytomegalovirus infections
- Focus Adverse reactions; Therapeutic Use
- 13 Mar 2024 Planned End Date changed from 30 Dec 2023 to 30 Dec 2024.
- 07 Feb 2023 Planned End Date changed from 14 Dec 2022 to 30 Dec 2023.
- 07 Feb 2023 Planned primary completion date changed from 14 Dec 2022 to 30 Dec 2023.